Gadoquatrane — Active Pharmaceutical Ingredient

Gadoquatrane is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: SOLUTION. Routes: INTRAVENOUS.

This content is for informational purposes only. Always consult a healthcare professional.

Gadoquatrane (1 brand name, 1 dosage form, 1 route)

Available dosage forms: SOLUTION.

Routes of administration: INTRAVENOUS.

Brand Names

  • AMBELVIST

Boxed Warning

Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. AMBELVIST is not approved for intrathecal use [see Warnings and Precautions (5.1)]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of AMBELVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), or Acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension, or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended AMBELVIST dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration [see Warnings and Precautions (5.2)].

Indications and Usage

AMBELVIST is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system)

Contraindications

AMBELVIST is contraindicated in patients with a history of severe hypersensitivity reactions to AMBELVIST.

Adverse Reactions

The following clinically significant adverse reactions are discussed elsewhere in the labeling: Nephrogenic Systemic Fibrosis [see Warnings and Precautions (5.2)] Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.3)]

Mechanism of Action

Gadoquatrane is a paramagnetic tetrameric macrocyclic non-ionic complex of gadolinium that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in the signal intensity (brightness) of tissues.

Overdosage

AMBELVIST can be removed by hemodialysis in the event of an overdose [see Clinical Pharmacology (12.3)]. For additional management recommendations, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.